Discovery and Treatment of the Early Autoimmune Reaction In Type 1 Diabetes

描述（由申请人提供）：本项目的目标是在NOD小鼠模型和人类中鉴定和表征I型糖尿病中最早的自身反应性T细胞和抗体。这将使用最近在P.I.实验室开发的基于化学库筛选的新技术来完成。它有助于无偏地搜索在患有特定疾病的患者血液中高度升高但在匹配对照中基本上不存在的抗原特异性抗体或T细胞。不需要了解抗体或T细胞识别的抗原。这一努力将解决外地几个尚未满足的关键需求。例如，我们将开发一种简单的血液测试，用于早期发病，希望是症状前的I型糖尿病。这将对这种疾病的管理产生深远的影响。我们还将构建一个完整的“历史”的不同抗原特异性自身免疫反应性，出现在NOD小鼠随着时间的推移。这应该有助于大量的基本知识，有关疾病发展的分子机制，在小鼠，也许在人类以及。最后，我们将评估一种新的治疗策略，其中使用靶向自身抗体和自身反应性T细胞受体的抗原结合位点的合成化合物阻断自身免疫性B和T细胞的活性。这一努力将为I型糖尿病和一般自身免疫性疾病的治疗指明一条革命性的道路，其中疾病的根本原因在不需要一般免疫抑制的情况下得到治疗。因此，我们相信，该项目的成功完成将对I型糖尿病的诊断、治疗和理解产生重大影响。 公共卫生相关性：该项目旨在确定参与I型糖尿病进展的新型抗体和T细胞。我们希望这将导致对早期疾病的有效诊断测试，并为一种新的治疗策略奠定基础，其中仅针对免疫系统的自身免疫成分。

DESCRIPTION (provided by applicant): The goal of this project is to identify and characterize the earliest autoreactive T cells and antibodies in type I diabetes, both in the NOD mouse model and in humans. This will be done using a novel chemical library screening-based technology recently developed in the laboratory of the P.I. It facilitates an unbiased search for antigen-specific antibodies or T cells that are highly elevated in the blood of patients with a particular disease, but are essentially absent in matched controls. No knowledge of the antigens recognized by the antibodies or T cells is required. This effort will address several unmet critical needs in the field. For example, we will develop a simple blood test for early onset, and hopefully pre-symptomatic, type I diabetes. This would have a profound impact on the management of this disease. We will also construct a complete "history" of the different antigen-specific autoimmune reactivities that arise in the NOD mouse over time. This should contribute a great deal of fundamental knowledge regarding the molecular mechanism of disease development in the mouse and perhaps in humans as well.. Finally, we will evaluate a novel therapeutic strategy in which the activities of the autoimmune B and T cells are blocked using synthetic compounds that target the antigen- binding sites of autoantibodies and autoreactive T cell receptors. This effort will point the way to a revolutionary approach to the treatment of type I diabetes, and autoimmune diseases in general, in which the root cause of the disease is treated without the need for general immunosuppression. Thus, we believe that the successful completion of this project will have a major impact on the diagnosis, treatment and understanding of type I diabetes. PUBLIC HEALTH RELEVANCE: This project aims to identify novel antibodies and T cells involved in the progression of type I diabetes. We hope that this will lead to effective diagnostic tests for early stage disease and also set the stage for a novel therapeutic strategy in which only the autoimmune components of the immune system are targeted.